SURVYR

MEDP

Medpace Holdings, Inc.
$673.79
−$2.98 (0.44%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-37%-24%-11%+2%+15%Oct 2025Oct 2026Apr 202652w high $677.9052w low $373.00
MEDPSPY
Wall St. Highest PT $700.00 (+3.9%) Wall St. Avg PT $595.92 (-11.6%)
$393$475$557$639$721POC $586Hi $700Avg $596
Underwater Drawdown %Max DD -36.6%Current -0.4%
0.0%-36.6%
Relative Strength vs SPY-0.6% vs SPYUnderperforming
+45%0%-45%
1W
+$51.36 (8.25%)
1M
+$54.91 (8.87%)
3M
+$102.82 (18.01%)
6M
+$264.14 (64.48%)
YTD
+$112.14 (19.97%)
1Y
+$77.31 (12.96%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
13 analysts · mean score 2.93
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$673.79
Average target$595.92
−$77.87 (−11.6%) downsideaverage target vs current price
CurrentAverageMedian
Low$370.00
Median$595.92
High$700.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$18.5B
P/E (last 12 months)38.9
P/E (next 12 months, estimated)34.3
52-week range$373.00 – $677.90
Revenue growth (latest quarter vs a year ago)+17.2%
Dividend yieldNo dividend
Analyst consensusHold (13)
Average analyst price target$595.92 (-12%)

What they do

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
39th percentile in sector
C-
12-1 return: +6.7%
Percentile within its GICS sector across the S&P 1500.
Growth
76th percentile in sector
B+
Revenue growth (YoY): +17.2%
Percentile within its GICS sector across the S&P 1500.
Value
15th percentile in sector
D-
Forward E/P: 3.1% · EBITDA/EV: 3.6%
Percentile within its GICS sector across the S&P 1500.
Profitability
88th percentile in sector
A
Profit margin: +17.7% · Return on equity: +162.2%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 66 of 589 · 12-month momentum 18.6%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MEDP earningsReported Oct 21, 2026▲ Above estimates
Results · After the close
EPS actual$4.84
EPS estimate$4.46
Surprise+8.5%
RevenueNot in our data yet

Revenue for this quarter is not in our data yet. It arrives with the quarterly filing.

Next report
Mon Feb 8, 2027Time not confirmed
EPS consensus$4.88
Revenue consensus–
Last 4 quarters · EPS vs estimate
Oct 21, 2026$4.84est $4.46+8.5%Above estimates
Jul 22, 2026$4.25est $4.00+6.2%Above estimates
Apr 22, 2026$4.28est $3.96+8.2%Above estimates
Feb 9, 2026$4.67est $4.23+10.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 18:15:33 ET
25-0225-0425-0725-1026-0226-0426-0726-100.004.84
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Medpace (MEDP) Q3 2026 Earnings Call Transcript
Nasdaq · Oct 22
Medpace (MEDP) files 8-K: results, other event
SEC 8-K · Oct 21
Stock Market Today: Nasdaq Pares Its Gains As SpaceX Rockets; Super Micro Shares Vault Higher (Live Coverage)
Investor's Business Daily · Oct 21
Insider trades
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-30
Sell
$13.7M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-29
Sell
$16.6M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-28
Sell
$1.5M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-25
Sell
$95.6K
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-24
Sell
$17.3M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-23
Sell
$10.1M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-22
Sell
$30.8M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-21
Sell
$13.6M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-17
Sell
$6.7M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-16
Sell
$5.4M
Troendle August J.
Director, President & CEO, 10% owner · 2026-09-15
Sell
$9.9M
Troendle August J.
Director, President & CEO, 10% owner · 2026-08-27
Sell
$403.2K

Stats refreshed 2026-10-27 18:15:33 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026